<DOC>
	<DOC>NCT01756482</DOC>
	<brief_summary>This study is to evaluate the antiviral effect of GS-5806 in healthy adults infected with a strain of Respiratory Syncytial Virus.</brief_summary>
	<brief_title>Safety and Efficacy Study of GS-5806 in Healthy Volunteers Infected With Respiratory Syncytial Virus (RSV)</brief_title>
	<detailed_description />
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Respiratory Syncytial Virus Infections</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>Healthy male or female Between 18 to 45 years old Body Mass Index of 18 to 33 kg/m2 Acute or chronic medical illness Positive for Human Immunodeficiency Virus, Hepatitis B or C Nose or nasopharynx abnormalities Abnormal lung function</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Respiratory</keyword>
	<keyword>Syncytial</keyword>
	<keyword>Virus</keyword>
	<keyword>Infections</keyword>
	<keyword>RSV</keyword>
</DOC>